{"filing":{"accession_number":"0001140361-26-034698","cik":"0001419041","ticker":"FBRX","company_name":"Forte Biosciences, Inc.","form":"8-K","filing_date":"2026-08-27","report_date":"2026-08-27","primary_document":"ef20081182_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1419041/000114036126034698/ef20081182_8k.htm"},"events":[{"id":30044,"run_id":27540,"accession_number":"0001140361-26-034698","anchor_item_number":"2.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.97,"summary":"Forte Biosciences completed a tender offer and merger transaction whereby a Purchaser acquired all outstanding shares for $77.00 per share in cash (87.13% tendered by August 26, 2026), with the Merger consummated on August 27, 2026 for approximately $2.2 billion in aggregate consideration, resulting in Forte becoming a wholly owned subsidiary of the Purchaser.","company_name":"Forte Biosciences, Inc.","ticker":"FBRX","filing_date":"2026-08-27","form":"8-K","submitted_at":null,"items":[{"id":32537,"accession_number":"0001140361-26-034698","item_number":"2.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.99,"reasoning":"This Item 2.01 discloses the completion of a tender offer and merger transaction whereby Purchaser acquired all outstanding shares of Forte Biosciences for $77.00 per share in cash, with 87.13% of shares tendered by the Expiration Date (August 26, 2026) and the Merger consummated on August 27, 2026 for approximately $2.2 billion in aggregate consideration. This is a material change of control and acquisition of the registrant.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-27T20:18:22.922840+00:00","company_name":"","ticker":null,"filing_date":""},{"id":32538,"accession_number":"0001140361-26-034698","item_number":"3.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The Item 3.01 disclosure references \"consummation of the Transactions\" and \"consummation of the Merger\" in connection with delisting. While Item 3.01 nominally covers delisting, the operative event here is the completion of a merger that triggered the delisting—the merger is the material transaction. The reference to Item 2.01 (which covers M\u0026A activity) reinforces that the merger is the principal event; delisting is a consequence. This is material to investors as it represents a change of control.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-27T20:18:22.922840+00:00","company_name":"","ticker":null,"filing_date":""},{"id":32540,"accession_number":"0001140361-26-034698","item_number":"5.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"Item 5.01 discloses consummation of an offer resulting in a change of control, with the Company becoming a wholly owned subsidiary of Parent. This is a completed acquisition/change of control transaction, which is a material M\u0026A event. The language \"consummation of the Offer\" and \"the Company became a wholly owned subsidiary of Parent\" are unmistakable indicators of a completed merger or acquisition.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-27T20:18:22.922840+00:00","company_name":"","ticker":null,"filing_date":""},{"id":32541,"accession_number":"0001140361-26-034698","item_number":"5.02","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"reasoning":"This Item 5.02 discloses the departure of all eight directors and all officers of Forte Biosciences in connection with the consummation of a merger transaction (the \"Transactions\"), with the Purchaser's directors and officers becoming the Company's directors and officers at the Effective Time. While the Item number is 5.02 (executive changes), the prose explicitly references Item 2.01 (the merger itself) and describes a complete change of control through a merger agreement, making the material event the M\u0026A activity rather than routine executive departures.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-27T20:18:22.922840+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":30045,"run_id":27540,"accession_number":"0001140361-26-034698","anchor_item_number":"5.03","event_type":"governance_other","event_domain":"governance","is_material":false,"confidence":0.75,"summary":"The Company's certificate of incorporation and bylaws were amended in connection with the merger consummation, a routine governance formality reflecting the mechanical restatement of governing documents at merger closing.","company_name":"Forte Biosciences, Inc.","ticker":"FBRX","filing_date":"2026-08-27","form":"8-K","submitted_at":null,"items":[{"id":32542,"accession_number":"0001140361-26-034698","item_number":"5.03","item_title":null,"event_type":"governance_other","event_domain":"governance","is_material":false,"confidence":0.75,"reasoning":"This Item 5.03 discloses amendments to the company's certificate of incorporation and bylaws in connection with a merger (referenced in Item 2.01). While the underlying merger is material, the Item 5.03 disclosure itself is a routine governance formality documenting the mechanical restatement of governing documents that occurs at merger closing. The substantive M\u0026A event is classified separately under Item 2.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-27T20:18:22.922840+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":30046,"run_id":27540,"accession_number":"0001140361-26-034698","anchor_item_number":"3.03","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.45,"summary":"Item 3.03 discloses a material modification to security holder rights by incorporating Items 2.01, 3.01, and 5.01; the specific nature of the modification cannot be determined without access to the full filing context.","company_name":"Forte Biosciences, Inc.","ticker":"FBRX","filing_date":"2026-08-27","form":"8-K","submitted_at":null,"items":[{"id":32539,"accession_number":"0001140361-26-034698","item_number":"3.03","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.45,"reasoning":"Item 3.03 discloses a material modification to security holder rights by incorporating Items 2.01 (business combination), 3.01 (delisting/listing), and 5.01 (changes in control). Without access to those referenced items, the specific nature of the modification cannot be determined—it could involve M\u0026A activity, delisting risk, or governance changes. The cross-reference structure prevents precise classification without the full filing context.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-27T20:18:22.922840+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":32537,"accession_number":"0001140361-26-034698","item_number":"2.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.99,"reasoning":"This Item 2.01 discloses the completion of a tender offer and merger transaction whereby Purchaser acquired all outstanding shares of Forte Biosciences for $77.00 per share in cash, with 87.13% of shares tendered by the Expiration Date (August 26, 2026) and the Merger consummated on August 27, 2026 for approximately $2.2 billion in aggregate consideration. This is a material change of control and acquisition of the registrant.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-27T20:18:22.922840+00:00","company_name":"Forte Biosciences, Inc.","ticker":"FBRX","filing_date":"2026-08-27"},{"id":32538,"accession_number":"0001140361-26-034698","item_number":"3.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The Item 3.01 disclosure references \"consummation of the Transactions\" and \"consummation of the Merger\" in connection with delisting. While Item 3.01 nominally covers delisting, the operative event here is the completion of a merger that triggered the delisting—the merger is the material transaction. The reference to Item 2.01 (which covers M\u0026A activity) reinforces that the merger is the principal event; delisting is a consequence. This is material to investors as it represents a change of control.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-27T20:18:22.922840+00:00","company_name":"Forte Biosciences, Inc.","ticker":"FBRX","filing_date":"2026-08-27"},{"id":32539,"accession_number":"0001140361-26-034698","item_number":"3.03","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.45,"reasoning":"Item 3.03 discloses a material modification to security holder rights by incorporating Items 2.01 (business combination), 3.01 (delisting/listing), and 5.01 (changes in control). Without access to those referenced items, the specific nature of the modification cannot be determined—it could involve M\u0026A activity, delisting risk, or governance changes. The cross-reference structure prevents precise classification without the full filing context.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-27T20:18:22.922840+00:00","company_name":"Forte Biosciences, Inc.","ticker":"FBRX","filing_date":"2026-08-27"},{"id":32540,"accession_number":"0001140361-26-034698","item_number":"5.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"Item 5.01 discloses consummation of an offer resulting in a change of control, with the Company becoming a wholly owned subsidiary of Parent. This is a completed acquisition/change of control transaction, which is a material M\u0026A event. The language \"consummation of the Offer\" and \"the Company became a wholly owned subsidiary of Parent\" are unmistakable indicators of a completed merger or acquisition.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-27T20:18:22.922840+00:00","company_name":"Forte Biosciences, Inc.","ticker":"FBRX","filing_date":"2026-08-27"},{"id":32541,"accession_number":"0001140361-26-034698","item_number":"5.02","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"reasoning":"This Item 5.02 discloses the departure of all eight directors and all officers of Forte Biosciences in connection with the consummation of a merger transaction (the \"Transactions\"), with the Purchaser's directors and officers becoming the Company's directors and officers at the Effective Time. While the Item number is 5.02 (executive changes), the prose explicitly references Item 2.01 (the merger itself) and describes a complete change of control through a merger agreement, making the material event the M\u0026A activity rather than routine executive departures.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-27T20:18:22.922840+00:00","company_name":"Forte Biosciences, Inc.","ticker":"FBRX","filing_date":"2026-08-27"},{"id":32542,"accession_number":"0001140361-26-034698","item_number":"5.03","item_title":null,"event_type":"governance_other","event_domain":"governance","is_material":false,"confidence":0.75,"reasoning":"This Item 5.03 discloses amendments to the company's certificate of incorporation and bylaws in connection with a merger (referenced in Item 2.01). While the underlying merger is material, the Item 5.03 disclosure itself is a routine governance formality documenting the mechanical restatement of governing documents that occurs at merger closing. The substantive M\u0026A event is classified separately under Item 2.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-27T20:18:22.922840+00:00","company_name":"Forte Biosciences, Inc.","ticker":"FBRX","filing_date":"2026-08-27"}]}